Abstract: The present invention provides a post-fabrication modification approach for the fabrication of colored and chromic materials and sensors using plasma surface modification to covalently bind the coloring agent to the substrate, thus avoiding leaching of the dye. Advantageously, in said methods, said coloring agent is a dye or pigment linked to a radical sensitive functional group, such as an alkenyl or alkynyl functional group, and is applied to the substrate prior to the gas plasma treatment. The methods envisaged herein are generic in nature, which allow the covalent immobilization of various dyes on different materials. The covalently coated materials after plasma surface modification, particularly the covalently coated chromic materials and sensors, can be used in many different applications, such as protective textile and wound dressing applications.

Abstract: The present invention relates to amorphous thermoresponsive polymers (ATP) and uses thereof in various domains, such as 3D printing and tissue engineering. Furthermore, the present invention relates to compositions, multidimensional structures and coatings comprising said polymer.

Abstract: Polyoxazoline polymers, polymer combinations, and compositions comprising those polymers or combinations of polymers are disclosed. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.

Abstract: The present invention relates to combinations of a poly(2-oxazoline) or poly(2-oxazine)5 polymer or copolymer having an allylamido side chain and a cross-linker, cross-linked compositions thereby obtained and hydrogels thereof. Further, the present invention discloses methods of providing the combination, compositions and hydrogels described herein and their use.

Abstract: The present invention relates to a method for creating a three- dimensional structure for cell growth by creating a template of a polymer, applying a hydrogel support onto the template and removing the template. The present invention further provides a device for cell growth comprising a polymer template embedded in a hydrogel.

Abstract: The present invention relates to polyoxazoline polymers, polymer combinations and compositions comprising those polymers or combinations of polymers. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.

Abstract: The present disclosure relates to the surface modification of substrates using poly (2-oxazine)s. Specifically, the present disclosure provides the use one or more poly(2-alkyl-2-oxazine) or copolymers containing poly(2-alkyl-2-oxazine) in surface modification of a substrate. More in particular the present disclosure provides substrates having attached thereto, or associated therewith, one or more poly(2-alkyl-2-oxazine) or copolymers containing poly(2-alkyl-2-oxazine); wherein said alkyl is preferentially selected from the list comprising methyl and ethyl. The present disclosure also provides methods for preparing such substrates and uses thereof.

Abstract: The present invention relates to the field of non-viral vectors and pharmaceutical compositions comprising polypropyleneimine and a nucleic acid, and their use in human or veterinary medicine. More precisely, the present invention relates to pharmaceutical compositions comprising a polymer or co-polymer of polypropyleneimine for delivery or transfection of a nucleic acid, e.g. RNA. The pharmaceutical compositions described herein are particularly useful for (nucleic acid) vaccination, nucleic acid-based protein therapy, nucleic-acid based protein replacement therapy, gene editing, base editing, cell therapy, immunotherapy, stem cell therapy, regenerative medicine, gene silencing, nucleic acid inhibition or protein inhibition.

Abstract: The present invention provides a post-fabrication modification approach for the fabrication of colored and chromic materials and sensors using plasma surface modification to covalently bind the coloring agent to the substrate, thus avoiding leaching of the dye. Advantageously, in said methods, said coloring agent is a dye or pigment linked to a radical sensitive functional group, such as an alkenyl or alkynyl functional group, and is applied to the substrate prior to the gas plasma treatment. The methods envisaged herein are generic in nature, which allow the covalent immobilization of various dyes on different materials. The covalently coated materials after plasma surface modification, particularly the covalently coated chromic materials and sensors, can be used in many different applications, such as protective textile and wound dressing applications.

Abstract: The invention entails the combination of basic catalysts, specifically guanidine-based catalysts, such as TBD, in conjunction with functionalized amines having a hydrogen bond donating or accepting functionality, to facilitate the accelerated transamidation of polymer compounds with non-activated ester side chains.

Abstract: The present invention provides a post-fabrication modification approach for the fabrication of colored and chromic materials and sensors using plasma surface modification to covalently bind the coloring agent to the substrate, thus avoiding leaching of the dye. Advantageously, in said methods, said coloring agent is a dye or pigment linked to a radical sensitive functional group, such as an alkenyl or alkynyl functional group, and is applied to the substrate prior to the gas plasma treatment. The methods envisaged herein are generic in nature, which allow the covalent immobilization of various dyes on different materials. The covalently coated materials after plasma surface modification, particularly the covalently coated chromic materials and sensors, can be used in many different applications, such as protective textile and wound dressing applications.

Abstract: The present invention, in general, relates to the field of poly(2-oxazolines) (PAOx), more in particular poly(2-methoxymethyl-2-oxazoline) (PMeOMeOX) and poly(2-dimethylamino-2-oxazoline) (PDMAOx). The present invention also provides methods for preparing these PAOx, as well as compositions and uses comprising said PAOx.

Abstract: The invention entails the combination of basic catalysts, specifically guanidine-based catalysts, such as TBD, in conjunction with functionalized amines having a hydrogen bond donating or accepting functionality, to facilitate the accelerated transamidation of polymer compounds with non-activated ester side chains.

Abstract: A biocompatible, covalently cross-linked, polymer that is obtained by reacting an electrophilically activated polyoxazoline (EL-POX) with a nucleophilic cross-linking agent is disclosed. The EL-POX comprises m electrophilic groups; and the nucleophilic cross-linking agent comprises n nucleophilic groups, wherein the m electrophilic groups are capable of reacting with the n nucleophilic groups to form covalent bonds; wherein m?2, n?2 and m+n?5; wherein at least one of the m electrophilic groups is a pendant electrophilic group and/or wherein m?3; and wherein the EL-POX comprises an excess amount of electrophilic groups relative to the amount of nucleophilic groups contained in the nucleophilic cross-linking agent. Biocompatible medical products and kits comprising the cross-linked POX-polymers are also disclosed.

Abstract: The present invention relates to polyoxazoline polymers, polymer combinations and compositions comprising those polymers or combinations of polymers. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.

Abstract: Cyclic imino ether polymers, such as polyoxazolines or polyoxazines, having a low polydispersity index can be obtained in a tubular flow reactor by applying a sufficiently high linear flow velocity of the reaction mixture in the tubular flow reactor, such as a flow velocity of least 100 cm/min or at least 120 cm/min. Also, methods to control the polydispersity of a cyclic imino ether polymer during polymerization are provided.

Abstract: The invention relates to invention relates to a statistical copolymer represented by the following formula (I): Ini-[Ox]m-[Oz]n-Nuc (I) wherein: Ini represents a residue of an initiator of cationic polymerization, Nuc represents a residue of a nucleophilic agent, Ox represents N(R1)CHRaCHRa; each R1 independently represents H or C(O)R11; and R11 independently represents optionally substituted C1-12 alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl or optionally substituted aryl; Oz represents N(R2)CHRaCHRaCHRa; each R2 independently represents C(O)R21 or H; and R21 independently represents optionally substituted C1-12 alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl or optionally substituted aryl; each Ra independently represents H, linear or branched C1-3 alkyl; m?5; n?5; m+n?20; 3:97?m:n?97:3.

Abstract: A method for production of a uniform polymer of high molar mass is provides, the method comprising: (a) polymerizing cyclic imino ether monomer in a first reaction mixture by cationic ring opening polymerization to produce a polymerized first reaction mixture containing (i) polymerized material and (ii) solvent and/or unreacted cyclic imino ether monomer; (b) separating solvent and/or unreacted cyclic imino ether monomer from polymerized material contained in the polymerized first reaction mixture; (c) copolymerizing by cationic ring opening polymerization a second liquid reaction mixture containing cyclic imino ether monomer and solvent by combining the separated unreacted cyclic imino ether monomer and/or the separated solvent with other components. Also disclosed are polyoxazoline polymers comprising at least 50 wt.

Abstract: The present invention provides peptide hydrogelators capable of forming hydrogels as carriers of active ingredients and acting as sustained or controlled release drug delivery systems.

Abstract: The present disclosure relates to the surface modification of substrates using poly (2-oxazine)s. Specifically, the present disclosure provides the use one or more poly(2-alkyl-2-oxazine) or copolymers containing poly(2-alkyl-2-oxazine) in surface modification of a substrate. More in particular the present disclosure provides substrates having attached thereto, or associated therewith, one or more poly(2-alkyl-2-oxazine) or copolymers containing poly(2-alkyl-2-oxazine); wherein said alkyl is preferentially selected from the list comprising methyl and ethyl. The present disclosure also provides methods for preparing such substrates and uses thereof.